Nomogram predicting leukopenia in osteosarcoma after high-dose methotrexate chemotherapy

被引:0
作者
Wu, Haixiao [1 ,2 ]
Xu, Guijun [2 ,3 ]
Li, Zhijun [1 ,2 ]
Xu, Yao [1 ,2 ]
Lin, Yile [2 ,5 ]
Chekhonin, Vladimir P. [2 ,6 ]
Peltzer, Karl [2 ,7 ]
Wang, Jun [8 ]
Li, Shu [2 ,9 ]
Li, Huiyang [2 ]
Zhang, Jin [1 ,2 ]
Xue, Yuan [2 ,3 ]
Ma, Wenjuan [1 ,2 ]
Wang, Xin [2 ,4 ]
Zhang, Chao [1 ,2 ]
机构
[1] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy,Tianjins Clin Res, Tianjin, Peoples R China
[2] Sino Russian Joint Res Ctr Bone Metastasis Malign, Tianjin, Peoples R China
[3] Tianjin Univ, Tianjin Hosp, Dept Orthoped, Tianjin, Peoples R China
[4] Army Med Univ, Affiliated Hosp 1, Dept Hlth Management Ctr Epidemiol & Biostat, Chongqing, Peoples R China
[5] Tianjin Med Univ, Dept Orthopaed Surg, Gen Hosp, Tianjin, Peoples R China
[6] Fed Med Res Ctr Psychiat & Narcol, Dept Basic & Appl Neurobiol, Moscow, Russia
[7] Univ Free State, Dept Psychol, Turfloop, South Africa
[8] Peoples Friendship Univ Russia, Med Inst, Dept Oncol Radiol & Nucl Med, Moscow, Russia
[9] Tianjin Univ Tradit Chinese Med, Sch Management, Tianjin, Peoples R China
来源
AGING-US | 2022年 / 14卷 / 12期
关键词
osteosarcoma; methotrexate; leukopenia; risk factor; nomogram; POPULATION PHARMACOKINETICS;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Purpose: To explore the trends of plasma drug concentration changes after high-dose methotrexate (MTX) treatment of osteosarcoma (OS), analyse the risk factors for leukopenia (LP) after MTX treatment, and establish a LP prediction nomogram. Methods: A total of 35 OS patients at Tianjin Medical University Cancer Institute and Hospital between 2017 and 2021 were collected (the construction cohort). Another 12 OS patients between 2019 and 2021 in P.A. Hertsen Moscow Oncology Research Center were involved (the external validation cohort). Peripheral venous blood MTX concentration (CMTX) was monitored at 0h, 6h, 24h, 48h and 72h after MTX administration. The characteristics were collected: age, sex, body surface area, lesion site, pathological subtype, pathological fractures, American Joint Committee on Cancer (AJCC) clinical stage, MTX dose, tumour necrosis, Ki-67 index, erythrocyte count, haemoglobin count, white blood cell count, platelet count (PLT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, albumin concentration, creatinine, alkaline phosphatase, and lactate dehydrogenase. Logistic regression analysis was used to determine the risk factors for LP occurrence. Significant factors were used to construct the prediction nomogram. Results: A total of 128 MTX chemotherapy cycles from 35 OS patients were included. Female, Ki-67>20%, C-MTX>112 mu mol/L at 6h, PLT, and AST were risk factors for post-chemotherapy LP occurrence. The LP prediction nomogram was created and validated. Conclusions: Female, C-MTX at 6h, Ki-67 index, AST and PLT before MTX treatment were risk factors for LP in OS patients who received MTX treatment. The established nomogram can guide personalized LP prediction in OS patients receiving MTX chemotherapy.
引用
收藏
页码:5023 / 5033
页数:11
相关论文
共 22 条
[1]   A review of methotrexate-associated hepatotoxicity [J].
Bath, Roopjeet K. ;
Brar, Navkiran K. ;
Forouhar, Faripour A. ;
Wu, George Y. .
JOURNAL OF DIGESTIVE DISEASES, 2014, 15 (10) :517-524
[2]   Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma [J].
Bernard, S. ;
Hachon, L. ;
Diasonama, J. F. ;
Madaoui, C. ;
Aguinaga, L. ;
Miekoutima, E. ;
Moatti, H. ;
Perrial, Emeline ;
Madelaine, I. ;
Brice, P. ;
Thieblemont, Catherine .
ANNALS OF HEMATOLOGY, 2021, 100 (04) :979-986
[3]   Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Casali, P. G. ;
Bielack, S. ;
Abecassis, N. ;
Aro, H. T. ;
Bauer, S. ;
Biagini, R. ;
Bonvalot, S. ;
Boukovinas, I. ;
Bovee, J. V. M. G. ;
Brennan, B. ;
Brodowicz, T. ;
Martin-Broto, J. ;
Brugieres, L. ;
Buonadonna, A. ;
De Alava, E. ;
Dei Tos, A. P. ;
Del Muro, X. G. ;
Dileo, P. ;
Dhooge, C. ;
Eriksson, M. ;
Fagioli, F. ;
Fedenko, A. ;
Ferraresi, V. ;
Ferrari, A. ;
Ferrari, S. ;
Frezza, A. M. ;
Gaspar, N. ;
Gasperoni, S. ;
Gelderblom, H. ;
Gil, T. ;
Grignani, G. ;
Gronchi, A. ;
Haas, R. L. ;
Hassan, B. ;
Hecker-Nolting, S. ;
Hohenberger, P. ;
Issels, R. ;
Joensuu, H. ;
Jones, R. L. ;
Judson, I. ;
Jutte, P. ;
Kaal, S. ;
Kager, L. ;
Kasper, B. ;
Kopeckova, K. ;
Krakorova, D. A. ;
Ladenstein, R. ;
Le Cesne, A. ;
Lugowska, I. ;
Merimsky, O. .
ANNALS OF ONCOLOGY, 2018, 29 :79-95
[4]   Population Pharmacokinetics of High-Dose Methotrexate After Intravenous Administration in Pediatric Patients With Osteosarcoma [J].
Colom, Helena ;
Farre, Rosa ;
Soy, Dolors ;
Peraire, Concepcion ;
Cendros, Josep-Maria ;
Pardo, Nuria ;
Torrent, Montserrat ;
Domenech, Josep ;
Mangues, Maria-Antonia .
THERAPEUTIC DRUG MONITORING, 2009, 31 (01) :76-85
[5]   Current and future therapeutic approaches for osteosarcoma [J].
Harrison, Douglas J. ;
Geller, David S. ;
Gill, Jonathan D. ;
Lewis, Valerae O. ;
Gorlick, Richard .
EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (01) :39-50
[6]   Preventing and Managing Toxicities of High-Dose Methotrexate [J].
Howard, Scott C. ;
McCormick, John ;
Pui, Ching-Hon ;
Buddington, Randall K. ;
Harvey, R. Donald .
ONCOLOGIST, 2016, 21 (12) :1471-1482
[7]   Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients [J].
Kawakatsu, Sonoko ;
Nikanjam, Mina ;
Lin, Mark ;
Le, Sonny ;
Saunders, Ila ;
Kuo, Dennis John ;
Capparelli, Edmund V. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (06) :1339-1348
[8]   Identifying risk factors for high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia [J].
Li, Xiao ;
Sui, Zhongguo ;
Jing, Fanbo ;
Xu, Wen ;
Li, Xiangpeng ;
Guo, Qie ;
Sun, Shuhong ;
Bi, Xiaolin .
CANCER MANAGEMENT AND RESEARCH, 2019, 11 :6265-6274
[9]   Risk Factors for Delayed Elimination of Methotrexate in Children, Adolescents and Young Adults With Osteosarcoma [J].
Misaka, Ko ;
Suga, Yukio ;
Staub, Yukiko ;
Tsubata, Atsumi ;
Shimada, Tsutomu ;
Sai, Yoshimichi ;
Matsushita, Ryo .
IN VIVO, 2020, 34 (06) :3459-3465
[10]   Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases [J].
Mori, Shunsuke ;
Hidaka, Michihiro ;
Kawakita, Toshiro ;
Hidaka, Toshihiko ;
Tsuda, Hiroyuki ;
Yoshitama, Tamami ;
Migita, Kiyoshi ;
Ueki, Yukitaka .
PLOS ONE, 2016, 11 (04)